All data are based on the daily closing price as of October 30, 2024
g
GNI Group
2160.TSE
19.92 USD
0.23
+1.17%
Overview
Last close
19.92 usd
Market cap
997.28M usd
52 week high
25.28 usd
52 week low
7.67 usd
Target price
26.78 usd
Valuation
P/E
21.5977
Forward P/E
N/A
Price/Sales
6.3406
Price/Book Value
3.8037
Enterprise Value
938.16M usd
EV/Revenue
5.2809
EV/EBITDA
11.2152
Key financials
Revenue TTM
154.46M usd
Gross Profit TTM
96.31M usd
EBITDA TTM
10.09M usd
Earnings per Share
0.91 usd
Dividend
N/A usd
Total assets
429.09M usd
Net debt
-63.97M usd
About
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.